Inj lon tesirin-lpyl 0.075mg
Products billed under this code include Zynlonta.
Payment limit per 0.075 MG, by effective quarter, 2Q22 to 4Q26. Gaps mean the code was not in that quarter’s file, or CMS gave no payment limit.Products billed under this code include Zynlonta.
Payment limit per 0.075 MG, by effective quarter, 2Q22 to 4Q26. Gaps mean the code was not in that quarter’s file, or CMS gave no payment limit.From the 4Q26 NDC–HCPCS crosswalk. “Limit / pkg” is the 4Q26 payment limit times the billing units in one package.
| Product | Labeler | NDC | Units / pkg | Limit / pkg |
|---|---|---|---|---|
| Zynlonta | ADC Therapeutics America, Inc. | 79952-0110-01 | 134 | $30,359.71 |
| Quarter | Payment limit | Change | Billing unit | Description | Source file |
|---|---|---|---|---|---|
| 4Q26 | $226.565 | −$0.043 | 0.075 MG | Inj lon tesirin-lpyl 0.075mg | v1, posted September 17, 2026 |
| 3Q26 | $226.608 | +$5.115 | 0.075 MG | Inj lon tesirin-lpyl 0.075mg | v1, posted September 15, 2026 |
| 2Q26 | $221.493 | +$0.271 | 0.075 MG | Inj lon tesirin-lpyl 0.075mg | v1, posted September 15, 2026 |
| 1Q26 | $221.222 | +$4.319 | 0.075 MG | Inj lon tesirin-lpyl 0.075mg | v1, posted September 15, 2026 |
| 4Q25 | $216.903 | +$0.16 | 0.075 MG | Inj lon tesirin-lpyl 0.075mg | v1, posted September 8, 2026 |
| 3Q25 | $216.743 | +$4.748 | 0.075 MG | Inj lon tesirin-lpyl 0.075mg | v1, posted March 10, 2026 |
| 2Q25 | $211.995 | −$0.123 | 0.075 MG | Inj lon tesirin-lpyl 0.075mg | v1, posted March 10, 2026 |
| 1Q25 | $212.118 | +$5.743 | 0.075 MG | Inj lon tesirin-lpyl 0.075mg | v1, posted December 19, 2025 |
| 4Q24 | $206.375 | −$0.039 | 0.075 MG | Inj lon tesirin-lpyl 0.075mg | v1, posted June 11, 2025 |
| 3Q24 | $206.414 | +$5.921 | 0.075 MG | Inj lon tesirin-lpyl 0.075mg | v1, posted June 11, 2025 |
| 2Q24 | $200.493 | −$0.134 | 0.075 MG | Inj lon tesirin-lpyl 0.075mg | v1, posted March 11, 2025 |
| 1Q24 | $200.627 | +$4.691 | 0.075 MG | Inj lon tesirin-lpyl 0.075mg | v1, posted December 19, 2024 |
| 4Q23 | $195.936 | −$0.513 | 0.075 MG | Inj lon tesirin-lpyl 0.075mg | v1, posted October 10, 2024 |
| 3Q23 | $196.449 | +$5.026 | 0.075 MG | Inj lon tesirin-lpyl 0.075mg | v1, posted June 5, 2024 |
| 2Q23 | $191.423 | −$0.387 | 0.075 MG | Inj lon tesirin-lpyl 0.075mg | v1, posted February 23, 2024 |
| 1Q23 | $191.81 | +$2.832 | 0.075 MG | Inj lon tesirin-lpyl 0.075mg | v1, posted December 6, 2023 |
| 4Q22 | $188.978 | +$0.683 | 0.075 MG | Inj lon tesirin-lpyl 0.075mg | v1, posted June 22, 2023 |
| 3Q22 | $188.295 | +$1.465 | 0.075 MG | Inj lon tesirin-lpyl 0.075mg | v1, posted June 9, 2023 |
| 2Q22 | $186.83 | – | 0.075 MG | Inj lon tesirin-lpyl 0.075mg | v1, posted December 14, 2022 |
“Change” is the difference from the previous quarter, shown only when both quarters have a payment limit and the billing unit is the same. “vs. last quarter” and “vs. a year ago” follow the same rule.